Illinois has confirmed its first human case of West Nile virus this year, health officials say. The person, who lives in ...

Senior doctors will be balloted on pay offer The BMA has announced indicative ballots of senior doctors in England, asking whether they are willing to take industrial action over their recent 4% pay ...

Valneva has been awarded $41m in funding from the CEPI and EU to expand access to its recently approved Ixchiq vaccine for chikungunya virus.

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing chikungunya disease in adults only, although, it is in clinical ...

IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)Antibody levels remained high after six months in both dose groups ...

Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companies, for the ...

Zeit Aktuelle Nachrichten; 17:48: Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance: Saint-Herblain (France), June 25, 2025 - Valneva SE (Nasdaq: VALN ...

The first, Ixchiq will likely provide long lasting protection from a single dose. A second vaccine – called Vimkunya – is non-live and will likely become available in the UK in August 2025; it ...

Six-month IXCHIQ chikungunya vaccine data demonstrates sustained antibody levels. Joshua Fitch, Senior Editor . June 5th 2025. Six-month results from the phase 2 VLA1553-221 trial aligned with initial ...